{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:04:42Z","timestamp":1792267482844,"version":"4.4.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A2C3007142, 2018R1A2A1A05076997, 2015M3A9B6066835"],"award-info":[{"award-number":["2019R1A2C3007142, 2018R1A2A1A05076997, 2015M3A9B6066835"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Blocking the immune evasion mechanism of tumor cells has become an attractive means for treating cancers. However, the usage of a drug such as nivolumab (\u03b1PD-1), which blocks programmed cell death protein 1 (PD-1), turned out to be only effective against certain types of cancer. Especially, vascular abnormal structures of which deter delivery route by leakage and cause the poor perfusion were considered to be environment unfavorable to T cells and immune checkpoint blockade (ICB) delivery within the tumor microenvironment (TME). Herein, we report stabilization of tumor blood vessels by endothelial dysfunctional blocker CU06-1004, which modified the TME and showed synergistic effects with immunotherapy anti-PD-1 antibody. CU06-1004 combination therapy consistently prolonged the survival of tumor-bearing mice by decreasing tumor growth. T-cell infiltration increased in the tumors of the combination group, with cytotoxic CD8<jats:sup>+<\/jats:sup> T cell activity within the tumor parenchyma upregulated compared with anti-PD-1 monotherapy. Tumor inhibition was associated with reduced hypoxia and reduced vessel density in the central region of the tumor. These effects correlated significantly with enhanced expression of IFN gamma and PD-L1 in tumors. Taken together, our findings suggest that CU06-1004 is a potential candidate drug capable of improving therapeutic efficacy of anti-PD-1 through beneficial changes in the TME.<\/jats:p>","DOI":"10.3389\/fimmu.2020.620166","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T06:14:00Z","timestamp":1611641640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells"],"prefix":"10.3389","volume":"11","author":[{"given":"Songyi","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hoon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeomyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Seul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Myeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Jun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Guen","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4508794","article-title":"Cancer Immunotherapy, Part 3: Challenges and Future Trends","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2015.1015888","article-title":"A new era in cancer immunotherapy: discovering novel targets and reprogramming the immune system","volume":"34","author":"Chiriva-Internati","year":"2015","journal-title":"Int Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","article-title":"The intracellular signalosome of PD-L1 in cancer cells","volume":"3","author":"Escors","year":"2018","journal-title":"Signal Transd Target Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2015.12.04","article-title":"Programmed cell death protein-1\/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role","volume":"4","author":"Santarpia","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17232","article-title":"PD1 signal transduction pathways in T cells","volume":"8","author":"Arasanz","year":"2017","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051389","article-title":"Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints","volume":"19","author":"Shi","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12883","article-title":"Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients","volume":"48","author":"Wang","year":"2019","journal-title":"J Oral Pathol Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4508794","DOI":"10.1155\/2019\/4508794","article-title":"Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates","volume":"2019","author":"Sambi","year":"2019","journal-title":"J Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3129","article-title":"Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy","volume":"77","author":"Zhao","year":"2017","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00211","article-title":"Vascular permeability and drug delivery in cancers","volume":"3","author":"Azzi","year":"2013","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00367","article-title":"The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy","volume":"8","author":"Klein","year":"2018","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_237987","article-title":"Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies","volume":"39","author":"Datta","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B18","doi-asserted-by":"publisher","first-page":"a006486","DOI":"10.1101\/cshperspect.a006486","article-title":"Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease","volume":"2","author":"Goel","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96582","article-title":"Increased vessel perfusion predicts the efficacy of immune checkpoint blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.06.139","article-title":"Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis","volume":"450","author":"Lee","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.04.104","article-title":"Sac-1004, a novel vascular leakage blocker, enhances endothelial barrier through the cAMP\/Rac\/cortactin pathway","volume":"435","author":"Maharjan","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12974-017-0897-3","article-title":"Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion injury by suppressing blood-brain barrier disruption and inflammation","volume":"14","author":"Zhang","year":"2017","journal-title":"J Neuroinflam"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0403","article-title":"Sustained Type I Interferon Reinforces NK Cell-Mediated Cancer Immunosurveillance during Chronic Virus Infection","author":"Oh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9585614","DOI":"10.1155\/2018\/9585614","article-title":"Immunotherapies: Exploiting the Immune System for Cancer Treatment","volume":"2018","author":"Koury","year":"2018","journal-title":"J Immunol Res"},{"key":"B25","article-title":"Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations","volume":"42","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau3259","article-title":"Targeted antibody and cytokine cancer immunotherapies through collagen affinity","volume":"11","author":"Ishihara","year":"2019","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","article-title":"Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040840","article-title":"Targeting Tumor Microenvironment for Cancer Therapy","volume":"20","author":"Roma-Rodrigues","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-020518-114700","article-title":"Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges","volume":"81","author":"Martin","year":"2019","journal-title":"Annu Rev Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-071813-105259","article-title":"The role of mechanical forces in tumor growth and therapy","volume":"16","author":"Jain","year":"2014","journal-title":"Annu Rev BioMed Eng"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031195","article-title":"Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity","volume":"6","author":"Martin","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/1471-2407-12-522","article-title":"Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments","volume":"12","author":"Nguyen","year":"2012","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transd Target Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improvecancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.10052","article-title":"Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL","volume":"56","author":"Gallego","year":"2003","journal-title":"Cytometry B Clin Cytom"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203543109","article-title":"Regulation of innate CD8+ T-cell activation mediated bycytokines","volume":"109","author":"Freeman","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1008824","DOI":"10.1080\/2162402X.2015.1008824","article-title":"Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression","volume":"4","author":"Bellucci","year":"2015","journal-title":"Oncoimmunology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of Resistance to PD-1 and PD-L1 Blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Curr Drug Targets"},{"key":"B45","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","article-title":"Fates of CD8+ T cells in Tumor Microenvironment","volume":"17","author":"Maimela","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3109\/02656731003601745","article-title":"Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer","volume":"26","author":"Lee","year":"2010","journal-title":"Int J Hyperthermia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.07.001","article-title":"Tumor Vasculatures: A New Target for Cancer Immunotherapy","volume":"40","author":"Liu","year":"2019","journal-title":"Trends Pharmacol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.620166\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T06:14:04Z","timestamp":1611641644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.620166\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2020.620166"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.620166","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"article-number":"620166"}}